Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

ClinicalTrials.gov ID: NCT07662122

Public ClinicalTrials.gov record NCT07662122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomised, Double-blind, Parallel-group, 42-week Dose-finding Trial for BI 3034701 Administered Subcutaneously Compared to Placebo in Participants With Obesity or Overweight

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.

Study identification

NCT ID
NCT07662122
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
342 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 74 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2026
Primary completion
Aug 3, 2027
Completion
Aug 17, 2027
Last update posted
Sep 9, 2026

2026 – 2027

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Cahaba Research, Inc. - Trussville Location Birmingham Alabama 35235
Focus Clinical Research West Hills California 91307
Optimus U Corporation-Miami-69452 Miami Florida 33135
Javara-Fayetteville-67354 Fayetteville Georgia 30214
Monroe Biomedical Research - Louisville Louisville Kentucky 40213
Arcturus Healthcare - Troy Internal Medicine Research Division Troy Michigan 48098
StudyMetrix Research, LLC City of Saint Peters Missouri 63303
Clinvest Research LLC Springfield Missouri 65807
Centricity Research - Morehead City Morehead City North Carolina 28557
Accellacare-Wilmington-67123 Wilmington North Carolina 28401
Lillestol Research, LLC Fargo North Dakota 58104
Tribe Clinical Research at Parkside OB-GYN, Greer Greer South Carolina 29650
Texas Diabetes and Endocrinology Austin Texas 78731
South Texas Research Institute - Brownsville Brownsville Texas 78520
South Texas Research Institute-Edinburg-67012 Edinburg Texas 78539
IMA Clinical Research San Antonio San Antonio Texas 78229
Data Point Clinical, LLC Kirkland Washington 98034
Rainier Clinical Research Center Renton Washington 98057
Allegiance Research Specialists Wauwatosa Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07662122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2026 · Synced Sep 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07662122 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →